RICHARD ALDRICH

CIK 1185039 · last filed 2023-03-06

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$70.95M

Companies

12

Total Filings

101

Lifetime Open-Market Net

$22.50M

Filer Profile

Reported Address
1365 MAIN STREET
WALTHAM, MA 02451
Related Filers
Peter Kolchinsky — 36 joint filings, latest 2008-11-21
RA CAPITAL MANAGEMENT, L.P. — 36 joint filings, latest 2008-11-21
RA Capital Healthcare Fund LP — 34 joint filings, latest 2008-11-21
RA Capital Healthcare Fund II, L.P. — 32 joint filings, latest 2008-11-21
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
CONCERT PHARMACEUTICALS, INC. (CNCE) Delisted Director 0 $8.37 $0 -$1.19M 20 2023-03-06
Tempest Therapeutics, Inc. (MLND) Delisted Director 4,687 $15.90 $74.5K $0 1 2018-12-11
KalVista Pharmaceuticals, Inc. (KALV) Delisted Director 934,484 $27.00 $25.23M $4.87M 5 2018-10-05
Tempest Therapeutics, Inc. (OVAS) Delisted Director 69,552 $8.55M 37 2018-10-02
PTCT Director 1,050,104 $65.65 $68.94M $11.11M 5 2015-06-10
VSTM Director 273,081 $7.34 $2.00M $270.2K 23 2013-11-12
BIOSPECIFICS TECHNOLOGIES CORP (BSTC) Delisted 10%+ Owner 690,309 $6.69M 4 2008-11-14
SEQUENOM INC (SQNM) Delisted 10%+ Owner 5,872,966 $0 1 2008-07-14
CRIS 10%+ Owner 3,125 $1.13 $3.5K -$9.10M 1 2008-04-17
ARADIGM CORP (ARDM) Delisted 10%+ Owner 189,210 $1.30M 1 2008-01-16
Sirtris Pharmaceuticals, Inc. (SIRT) Delisted Director 38,095 $0 1 2007-05-31
LIPID SCIENCES INC/ (LIPD) Delisted 10%+ Owner 3,713,962 $1.7K 1 2007-03-28

Recent Filings · Page 6 of 11

101 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2015-07-02 Tempest Therapeutics, Inc. (OVAS) Delisted Grant (A) +367 $10.6K EDGAR
2015-06-15 CONCERT PHARMACEUTICALS, INC. (CNCE) Delisted Grant (A) $0 EDGAR
2015-06-10 PTCT Mixed -$313.6K EDGAR
2015-06-08 Tempest Therapeutics, Inc. (OVAS) Delisted Grant (A) $0 EDGAR
2015-04-09 Tempest Therapeutics, Inc. (OVAS) Delisted Buy (P) +2,500 $74.9K EDGAR
2015-04-02 Tempest Therapeutics, Inc. (OVAS) Delisted Grant (A) +305 $10.6K EDGAR
2015-01-02 PTCT Grant (A) $0 EDGAR
2014-10-21 CONCERT PHARMACEUTICALS, INC. (CNCE) Delisted Gift (G) $0 EDGAR
2014-07-16 Tempest Therapeutics, Inc. (OVAS) Delisted Buy (P) +1,000 $9.5K EDGAR
2014-07-09 Tempest Therapeutics, Inc. (OVAS) Delisted Buy (P) +2,000 $19.0K EDGAR
Showing 5160 of 101
Page 6 of 11
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.